Compare Figs Inc (FIGS) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Gilead Sciences, Inc. — how do they compare? Figs Inc trades at $14.96 (market cap $2.34B), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 77.8× Figs Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Figs Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Gilead Sciences, Inc. for 111 Days on average.
| FIGS | GILD | |
|---|---|---|
Market Cap | $2.34B | $182.09B |
Volume | 6,865,366 | 4,960,247 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $155.80 |
52-Week Low | $6.90 | $116.74 |
Typical Hold Time | 33 Days | 111 Days |
Enterprise Value | $2.10B | $205.15B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $14.98, up 6.24% today, with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth, with 2025 revenue reaching $631.10M and net income of $34.25M. Recent earnings beats and raised 2026 guidance signal operational strength, though valuation multiples remain elevated with a P/E of 42.61. International expansion continues to drive growth, with Q2 international sales surging 67%.
The outlook remains positive with analyst consensus pointing to 26.4% upside potential to $18.00 target. Strong fundamentals and momentum are balanced by rich valuation requiring continued execution. Key risks include premium pricing pressure and competitive threats in healthcare apparel. Wall Street sentiment leans bullish with 60% buy ratings among 15 analysts covering the stock.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
